Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | PAM | P19021 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2683579 | 0.79 | PTGER4 (0.45) | NPC1POLBKMT2AMEN1IDO1 | |
| SCHEMBL2683581 | 0.79 | PTGER4 (0.45) | NPC1POLBKMT2AMEN1IDO1 | |
| SCHEMBL2012568 | 0.78 | IDO1 (0.45) | ALOX5NPC1POLBIDO1PAM | |
| SCHEMBL2012572 | 0.78 | IDO1 (0.45) | ALOX5NPC1POLBIDO1PAM | |
| SCHEMBL2015024 | 0.77 | NPC1 (0.41) | NPC1KMT2AMEN1RAB9A | |
| SCHEMBL2015026 | 0.77 | NPC1 (0.41) | NPC1KMT2AMEN1RAB9A | |
| SCHEMBL2010703 | 0.74 | IDO1 (0.46) | ALOX5IDO1PAM | |
| SCHEMBL2010704 | 0.74 | IDO1 (0.46) | ALOX5IDO1PAM | |
| SCHEMBL8625969 | 0.72 | IDO1 (0.47) | IDO1PAM | |
| SCHEMBL8621304 | 0.71 | IDO1 (0.53) | IDO1PAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101075-A2 | Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 Adrenergic Receptor | LABORATORIOS ALMIRALL, S.A. (ES) | 2012-04-26 | — | — | US | disclosed |
| EP-1885684-B9 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA-2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2012-04-25 | — | — | EP | disclosed |
| US-20110251166-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | PUIG DURAN CARLOS | 2011-10-13 | — | — | US | disclosed |
| US-20110251165-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. | 2011-10-13 | — | — | US | disclosed |
| EP-1885684-B1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA-2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2011-07-13 | — | — | EP | disclosed |
| US-7964615-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2011-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251166-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRA2C, ADRB1 | PPARG 584/4885PTGES 1493/4885ALOX5 2454/4885 |
| US-20110251165-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRA2C, ADRB3 | PPARG 630/4885PTGES 1448/4885ALOX5 2631/4885 |
| US-20120101075-A2 | Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 Adrenergic Receptor | ADRB2, ADRB1, ADRA2C | PPARG 133/4885PTGES 548/4885ALOX5 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.